ストックスクリーナーアプリを入手
81.48
0.55%
-0.45
アフターアワーズ：
81.48
前日終値:
$81.93
開ける：
$82.41
24時間の取引高:
1.44M
Relative Volume:
0.80
時価総額：
$9.66B
収益：
$1.51B
当期純損益:
$348.84M
株価収益率:
29.30
EPS:
2.7805
ネットキャッシュフロー:
$667.65M
1週間 パフォーマンス:
+5.69%
1か月 パフォーマンス:
+8.70%
6か月 パフォーマンス:
+16.04%
1年 パフォーマンス:
+39.90%
1日の値動き範囲:
$81.46
$83.50
1週間の範囲:
$76.82
$83.50
52週間の値動き範囲:
$57.67
$83.50
Halozyme Therapeutics Inc Stock (HALO) Company Profile
名前
Halozyme Therapeutics Inc
セクター
電話
(858) 794-8889
住所
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
81.48 | 9.72B | 1.51B | 348.84M | 667.65M | 2.7805 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-04 | ダウングレード | Goldman | Neutral → Sell |
| 2025-10-14 | アップグレード | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 再開されました | Goldman | Neutral |
| 2025-05-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | ダウングレード | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2024-06-07 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 開始されました | TD Cowen | Outperform |
| 2023-07-24 | ダウングレード | Goldman | Buy → Neutral |
| 2023-07-24 | 開始されました | H.C. Wainwright | Buy |
| 2023-05-10 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 再開されました | Berenberg | Buy |
| 2023-03-16 | ダウングレード | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 再開されました | Morgan Stanley | Overweight |
| 2022-11-28 | 開始されました | Wells Fargo | Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Outperform |
| 2021-06-14 | 開始されました | Evercore ISI | Outperform |
| 2021-05-17 | 開始されました | SVB Leerink | Outperform |
| 2021-05-11 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 繰り返されました | The Benchmark Company | Buy |
| 2020-12-17 | 開始されました | Berenberg | Buy |
| 2020-09-14 | 再開されました | JP Morgan | Overweight |
| 2020-07-01 | 開始されました | The Benchmark Company | Buy |
| 2020-02-05 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 開始されました | Goldman | Buy |
| 2019-11-05 | アップグレード | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 再開されました | Piper Jaffray | Neutral |
| 2018-05-11 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 開始されました | Goldman | Neutral |
| 2017-10-16 | 繰り返されました | Piper Jaffray | Overweight |
| 2017-01-06 | ダウングレード | Citigroup | Buy → Neutral |
| 2016-11-03 | 開始されました | Deutsche Bank | Buy |
| 2015-12-04 | 開始されました | Wells Fargo | Outperform |
| 2015-11-18 | 開始されました | Citigroup | Buy |
| 2015-09-22 | 開始されました | Barclays | Overweight |
| 2015-06-22 | 繰り返されました | JP Morgan | Overweight |
| 2015-03-03 | 繰り返されました | UBS | Buy |
| 2015-02-18 | 繰り返されました | MLV & Co | Buy |
| 2015-01-08 | 繰り返されました | MLV & Co | Buy |
すべてを表示
Halozyme Therapeutics Inc (HALO) 最新ニュース
Halozyme Therapeutics Inc (HALO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
HALO|Halozyme Therapeutics Inc|Price:81.930|Chg%:+1.090 - TradingKey
Halozyme Therapeutics (RV7) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (HALO) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (HALO) Q4 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics, Inc. Revenue Breakdown – BX:RV7 - TradingView
Halozyme Therapeutics (HALO) Q3 2025 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (HALO) Q2 2025 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics, Inc. (HALO) Stock Price, News, Quote & History - Yahoo! Finance Canada
Halozyme Therapeutics (HALO) Q1 2025 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics, Inc. (HALO) stock price, news, quote and history - Yahoo Finance Australia
Halozyme Therapeutics (HALO) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (HALO) Q2 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics, Inc. (HALO) Options Chain - Yahoo! Finance Canada
HALO5638653 Bond Profile — Key Metrics - TradingView
HALO5638653 Bond Coupon Profile — Rate & Payments - TradingView
Halozyme Therapeutics stock hits all-time high at 82.42 USD - Investing.com
Halozyme Therapeutics Inc (HALO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Halozyme Therapeutics to report Q2 2026 results on August 6 - scanx.trade
Halozyme to host Aug. 6 call on second-quarter results - Stock Titan
Halozyme to report Q2 results after market close, host conference call - Bitget
Analysts Offer Insights on Healthcare Companies: Halozyme (HALO), Phathom Pharmaceuticals (PHAT) and Incyte (INCY) - The Globe and Mail
Halozyme Therapeutics (HALO) Lands Incyte Deal On A Valuation That Still Looks Undervalued - Sahm
Halozyme’s Partnerships, Earnings Growth See Shares Near All-Time Highs - Yahoo Finance
Should Halozyme’s New ENHANZE–Incyte Oncology Pact Reshape How HALO Investors View Its Royalty Model? - Sahm
Benchmark reiterates Halozyme stock Buy rating on Incyte deal - Investing.com UK
Benchmark reiterates Halozyme stock Buy rating on Incyte deal By Investing.com - Investing.com South Africa
Did Halozyme’s (HALO) New Incyte Enhanze Deal Just Redefine Its Precision Oncology Royalty Engine? - Yahoo Finance
HALO Inks Deal With INCY to Support Cancer Therapy Development - Yahoo Finance
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE Technology - marketscreener.com
HALO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $95 - GuruFocus
H.C. Wainwright reiterates Incyte stock rating on Halozyme deal By Investing.com - Investing.com Canada
Halozyme (HALO) Partners with Incyte to Advance Drug Delivery Te - GuruFocus
Halozyme and Incyte sign licence agreement for INCA033989 formulations - Yahoo Finance
Halozyme Therapeutics (HALO) Secures Global Deal with Incyte for Innovative Drug Delivery - GuruFocus
Halozyme enters license agreement with Incyte - The Pharma Letter
Halozyme, Incyte to Collaborate on Development of Subcutaneous mAb Formulations - Contract Pharma
Halozyme and Incyte announce global collaboration deal - grafa.com
Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development - Yahoo Finance
Halozyme (HALO) Partners with Incyte to Advance Drug Delivery Technology - GuruFocus
Halozyme partners with Incyte on drug delivery technology - Investing.com
Halozyme partners with Incyte on drug delivery technology By Investing.com - Investing.com South Africa
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology - PR Newswire
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: A Booming Biotech with a 42.2% Revenue Growth - DirectorsTalk Interviews
Halozyme partners with Incyte to evaluate subcutaneous formulations - scanx.trade
Technical Reactions to HALO Trends in Macro Strategies - Stock Traders Daily
Halozyme Therapeutics (HALO) Gets A Lift As Darzalex Faspro Trial Improves Survival - Sahm
ETFs Investing in Halozyme Therapeutics, Inc. Stocks - TradingView
Halozyme Therapeutics (0J2O) Q1 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (0J2O) Q4 2025 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics (0J2O) Q3 2024 Earnings ReportResults, Call & Slides - TipRanks
Halozyme Therapeutics Inc (HALO) 財務データ
収益
当期純利益
現金流量
EPS
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):